why choose us

First received: September 05, 2023

Clinical Trial: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Study Status: Completed

Recruit Status: RECRUITING

Condition: Acute Myeloid Leukemia

Study Type: INTERVENTIONAL


Official Title: An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD

Brief Summary: Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

Read more